Company Performance Metrics
- Robert Claypoole: President and Chief Executive OfficerPast Role: Mölnlycke, Executive Vice President, Wound Care
Bill Hawkins: Chairman and CEO
Bioventus is a global leader of active orthopaedic healing, providing clinically proven and cost-effective therapies and diagnostics that help patients regain active lifestyles.
Bioventus' products are known for their innovation, safety and effectiveness. The company is the recognized leader in bone stimulation devices and among the
leading distributors of osteoarthritis joint fluid therapies. Key products include:
- EXOGEN(r) Ultrasound Bone Healing System
- SUPARTZ(r) Joint Fluid Therapy (US only)
- DUROLANE(r) Hyaluronic Acid, Single Injection (Outside US only)
Bioventus' adherence to high quality standards, commitment to evidence-based medicine and strong ethical behavior makes the company a trusted partner for thousands of physicians worldwide.
Bioventus employs 500 people and generates about $240 million in yearly revenue. The company is headquartered in Durham, N.C. Prior to launch in 2012, Bioventus was operating as the Biologics Division of Smith & Nephew.
